A class action lawsuit has been filed against Fractyl Health, accusing the company of misleading investors about the effectiveness of its Revita DMR System for treating type 2 diabetes and obesity. The complaint alleges that Fractyl overstated the therapy's efficacy and failed to disclose operational issues affecting clinical trial results. Following disappointing six-month data released in January 2026, Fractyl's stock price plummeted over 68%, with further declines after a Morgan Stanley downgrade. Investors who bought shares between January 2025 and January 2026 may join the lawsuit, with a lead plaintiff deadline set for October 20, 2026.
Jeff Bezos sold $346 million of Amazon stock on August 3, 2026, coinciding with a peak in Amazon's share price. However, the stock declined about 14% since then, pressured by regulatory concerns, a lawsuit from the FTC and 22 states over advertising ...
Bloom Energy is addressing power supply challenges for AI data centers by providing on-site fuel cell solutions that enable faster deployment. The company reported strong Q2 results with $1.06 billion in revenue, a 166% increase year-over-year, a 17....
Solana (SOL) experienced a 2.01% price decline within one hour, falling to $120 as measured on Binance's spot market. This extended its 24-hour loss to 0.60%. During the same hour, liquidations totaled approximately $2.48 million for long positions a...
OpenAI reported rapid growth with a $70 billion annualized revenue run-rate and 70% sequential growth as of Q3 2026, driven by enterprise adoption of new AI features like Private Intelligence. Despite deep net losses of $38.5 billion in FY25 due to a...
Intel could see significant stock gains if it successfully grows its server processor business and improves manufacturing yields. The company’s advanced packaging technology may add new revenue streams, but sustained profitability depends on strong i...
